Tevogen Bio (NASDAQ:TVGN) Stock Rockets On Huge News
The new week started off on a highly positive note for Tevogen Bio (NASDAQ:TVGN) shareholders as the company’s stock experienced heavy action yesterday and clocked gains of 187% for the day.
Tevogen Bio (NASDAQ: TVGN) Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
On October 11, the company provided a sneak peek into its potential of turning into a $1 billion plus revenue business thanks to its unique approach to business. It was noted that in the current market situation, the approach followed by Tevogen Bio offered the most cost-effective and unique drug development model.
The model could help usher in an era of sustainable innovation in the medical space for many years. It was also asserted that Tevogen Bio had more than three decades of experience and strong business fundamentals, which placed the company in a strong position to provide cures for some of the most urgent health conditions.
CEO Speak
Yesterday, the company’s Chief Executive Officer, Ryan Saadi, spoke about the ‘information gap’ with shareholders. He stated that the company valued the shareholder’s trust and took it with the highest seriousness.
He went on to note that the company was committed to bridging the information gap so as to make sure that the shareholders had higher visibility of the progress being made by Tevogen Bio. It remains to be seen if the stock can add to its gains today.
Technicals
| +/- EMA(20) | 0.53 (+158.49%) |
| +/- SMA(50) | 0.51 (+168.63%) |
| +/- SMA(200) | 1.91 (-28.27%) |
| 5-Day Perf. | +336.44% |
| 1-Month Perf. | +186.01% |
| 3-Month Perf. | +92.98% |
| 6-Month Perf. | -41.7% |
| YTD Perf. | – |
| 1-Year Perf. | – |
| RSI(14) | 86 |
| ATR(14) | 0.15 |
| ADX(14) | 37.29 |
| Beta (5Y) | 2.40 |
